Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FMED2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $34,982
Award facts
- Contract value 100% obligated
- $34,982.36 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a $34,982.36 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The delivery order, issued on January 2, 2026, with an ultimate completion date of January 26, 2026, carries no set-aside designation, indicating the company competed successfully in an unrestricted procurement environment. This award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy with a ceiling value of $499,999,999 and a completion date of December 31, 2036. The PPV-G GEN V program establishes multiple regional prime vendor contractors to provide comprehensive pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group's selection as a prime vendor under this strategic initiative reflects its demonstrated capability to supply specialized pharmaceutical products, including oncology treatments such as Keytruda, to federal military medical systems. The company's substantial portfolio encompasses a broad range of therapeutic categories and product lines, positioning it as a critical supplier within the federal pharmaceutical supply chain. As a registered small business in the System for Award Management since July 2001, DMS Pharmaceutical Group continues to leverage its status to compete effectively in government procurement while maintaining consistent contract performance across multiple delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division.
Quick answers
Who was awarded contract SPE2DR26FMED2?
SPE2DR26FMED2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 2, 2026.
How much is contract SPE2DR26FMED2 worth?
The government has obligated $34,982 on SPE2DR26FMED2.
Is contract SPE2DR26FMED2 an order under another contract?
Yes. SPE2DR26FMED2 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMED2 competed?
The extent of competition for SPE2DR26FMED2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award